Deborah L. White

Frome Road
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

The partner gene modulates response to asciminib in ABL1-rearranged Acute Lymphoblastic Leukemia.

Journal: Neoplasia (New York, N.Y.)
Published: April 21, 2026

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Mitochondrial DNA mutations are associated with impaired oxidative phosphorylation and enhanced imatinib response in chronic myeloid leukemia.

Journal: HemaSphere
Published: March 18, 2026

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib.

Journal: Leukemia
Published: March 10, 2026

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

The gastrointestinal microbiome and constituent short-chain fatty acids: a narrative review of an underexplored axis in acute lymphoblastic leukemia.

Journal: Gut pathogens
Published: February 24, 2026

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Central nervous system involvement in acute lymphoblastic leukemia: pathogenesis and targeted therapy.

Journal: Leukemia
Published: December 17, 2025

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Identification of a Novel, Oncogenic and Targetable TPR::ABL2 Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia.

Journal: EJHaem
Published: October 30, 2025

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.

Journal: British journal of haematology
Published: September 14, 2025

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.

Journal: Pediatric blood & cancer
Published: August 28, 2025

Biological and clinical characteristics of ETV6::RUNX1-like ALL.

Biological and clinical characteristics of ETV6::RUNX1-like ALL.

Journal: HemaSphere
Published: August 28, 2025

Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic Vulnerabilities.

Journal: Cancers
Published: August 14, 2025

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" study.

Journal: HemaSphere
Published: July 23, 2025

Asciminib for Philadelphia chromosome-positive leukemias.

Asciminib for Philadelphia chromosome-positive leukemias.

Journal: Haematologica
Published: March 31, 2025
Showing 1-12 of 120

Last Updated: 09/26/2026